13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Artificial Intelligence in Neurology and Neurosurgery
The application of Artificial Intelligence (AI) in neurology and neurosurgery is reshaping how neurological disorders are diagnosed and treated. AI tools assist in analyzing electrophysiological signals and neuroimaging scans with remarkable accuracy, improving early detection and intervention. In surgical contexts, AI-driven robotics enhance precision and efficiency, especially in intricate procedures like brain and spinal surgeries. Predictive analytics supported by machine learning enables tailored treatment plans, considering the unique characteristics of each patient. AI also fosters advancements in neurorehabilitation, with intelligent systems aiding recovery through adaptive therapies. This evolving technology is setting new benchmarks for excellence in neurological healthcare.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States